Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
Sooyoung Shin, Sukhyang LeeAjou University College of Pharmacy, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea Abstract: Nearly all patients with end-stage renal disease develop hyperphosphatemia. These patients typically require oral phosphate binders for life-long phosphorus management, in addition t...
Guardado en:
Autores principales: | Shin S, Lee S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d9427cb8ec646d2955c082f3859ba55 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome
por: Ohanian M, et al.
Publicado: (2011) -
Attenuation of niacin-induced prostaglandin D2 generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells
por: VanHorn J, et al.
Publicado: (2012) -
Melatonergic drugs in development
por: Carocci A, et al.
Publicado: (2014) -
Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review
por: Aguirre Valadez J, et al.
Publicado: (2015) -
Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson DJ, et al.
Publicado: (2014)